Original Research Article

A study of biofilm production and antimicrobial susceptibility pattern among urinary isolates

Ashwini Rajmane¹, Pankaj A Joshi¹-*, Vishakha Shikhare¹, Meena Ramteerthakar¹, Vanita Kulkarni¹

1 Dept. of Microbiology, Government Medical College, Miraj, Maharashtra, India

A R T I C L E  I N F O

Article history:
Received 29-09-2021
Accepted 06-10-2021
Available online 15-12-2021

Keywords:
Biofilm
Urinary isolates
Antimicrobial susceptibility

A B S T R A C T

Background and Objectives: Urinary tract infection (UTI) is the most commonly acquired bacterial infection. Bacterial biofilms play an important role in urinary tract infections and are responsible for persistent infections as well as higher antimicrobial resistance. The microbial biofilms pose a public health problem as the microorganisms in the biofilms are difficult to treat with antimicrobial agents. So the present study was undertaken with the aim to study biofilm production and antimicrobial susceptibility pattern of urinary isolates.

Materials and Methods: Aerobic bacterial isolates from urine samples submitted to microbiology laboratory for culture were included in the study. The isolates were tested for biofilm formation by Congo red agar method and Christensen tube method. Antimicrobial susceptibility tests were performed on these isolates by Kirby Bauer disk diffusion method as per CLSI guidelines. A total of 293 Gram negative bacilli and 59 Gram positive cocci were tested for biofilm production and antimicrobial susceptibility testing.

Results: Gram-negative organisms were predominant (83.24%) of all the isolates. Biofilm production was detected in 47% of the isolates. Pseudomonas aeruginosa (51.7%), were the most common biofilm producing Gram negative bacilli followed by Escherichia coli (44.32%). Amongst Gram positive cocci, Enterococcus faecalis (77.8%) was the most common biofilm producing organism. Biofilm producing urinary isolates displayed relatively less percentage of antimicrobial susceptibility than biofilm non producers.

Conclusion: Biofilm forming isolates showed higher antimicrobial resistance as compared to biofilm non producer. Early detection of biofilm production in urinary isolates may aid clinicians in treatment of urinary tract infections.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Urinary tract infections (UTIs) are one of the most important causes of morbidity and health care spending, affecting persons of all ages.¹ Urinary tract infections (UTI) pose a serious health threat due to the high recurrence rates and antimicrobial resistance in the causative agents.² The risk of developing urinary tract infection increases significantly with the use of indwelling devices such as catheters and urethral stents.³ Biofilms are an assembly of microbial cells formed by single or a mixture of bacterial species that are irreversibly associated with a surface and enclosed in a matrix of polysaccharide materials that allow the growth and survival in hostile environments. Biofilms confer advantages to the biofilm forming bacteria, such as protection from antimicrobial agents, exchange of nutrients and metabolites, and/or genetic exchange between organisms. Limited penetration of antibiotics into
biofilm and slow rate of cell multiplication of organisms in the biofilm may contribute to the development of chronic infections. Biofilm can be found in the urothelium, renal stones, and implanted foreign bodies. Several studies observed that most of the urinary isolates collected from patients with relapse infections were biofilm producers “in vitro”. Relapse by uropathogenic *Escherichia coli* (UPEC) has been related to the ability of pathogenic strains to form biofilm. In these cases, biofilm production may be the key determinant for the persistence of UPEC in the vaginal reservoir, the bladder epithelial cells or both.

Most studies conducted previously focus on either biofilm production by a single microbe causing UTI or biofilm formation only in catheterized patients. This study includes the entire spectrum of bacteria causing UTI in catheterized and non-catheterized patients. The study will provide a baseline data of biofilm producing organisms responsible for UTI in this area as well as the susceptibility pattern of biofilm producing and non-producing organisms. The study may also provide information about the various factors including indwelling catheters, predisposing for infections due to biofilm producing organisms.

2. Materials and Methods

A prospective observational study was conducted in the Microbiology laboratory of a tertiary care hospital, for a period of one and half years, after obtaining approval from the institutional ethics committee. The study included 352 urine samples submitted to Microbiology laboratory for culture and sensitivity.

2.1. Inclusion criteria

Aerobic bacterial isolates from urine samples collected from all clinically suspected patients of urinary tract infection admitted in IPD and attending OPD who are willing to participate in the study.

2.2. Exclusion criteria

Fungal isolates. Patients not willing to participate in this study.

Informed consent from all the patients included in the study was taken prior to initiation of the study.

2.3. Methodology

Mid-stream, clean catch urine samples from non-catheterised patients and aseptically aspirated urine of catheterised patients, submitted to Microbiology laboratory for aerobic bacterial culture, were included in the study. All samples were processed for aerobic bacterial culture by inoculating on blood agar, MacConkey agar and Congo red agar by semi quantitative method. The growth on these media were observed and analysed after incubating for 24 hours at 37°C. The isolates grown on blood agar and/or Mac-Conkey agar were identified based on the colony morphology, Gram’s staining and standard biochemical tests. The growth on Congo red agar (CRA) was observed for black colour. Antimicrobial susceptibility testing for all the isolates was performed by Kirby-Bauer disc diffusion method as per the CLSI 2017 guidelines. Biofilm detection was done by using Congo red agar method and Christensen’s tube method. Biofilm detection was done by using Congo red agar method and Christensen’s tube method. (Figure 1)

2.4. Congo red agar (CRA) method

The colony of the isolates grown on blood agar or MacConkey agar was inoculated on Congo red agar plate. Congo red agar was prepared as per the method described by Freeman et al. (1989). The urine samples were inoculated on Congo red agar medium and after overnight incubation, colonies were observed. The growth on CRA was observed after overnight incubation at 37°C for 24 hours. The black colonies with dry metallic consistency were considered as positive test (slime producers). Non slime producers usually remained pink.

2.5. Tube method

The method used was the one which was described by Christensen et al 1982. The colonies on blood agar and MacConkey agar were inoculated in tryptic soy broth with one percent glucose. After overnight incubation, the tubes were decanted and washed three times with phosphate buffered saline to remove planktonic flora and then stained with safranin. The visible pink film lining inside the tube was considered as positive test. The line at liquid air interface though stained pink was not considered as positive
result.\(^8\) (Figure 2)

![Image of biofilm production detection](image)

**Fig. 2:** Detection of biofilm production by tube method

The strains were considered to be biofilm producers when both the tests were positive. They were considered to be biofilm non-producers if both the tests were negative. If the discrepant results (only one test positive) were observed for an isolate it was included in biofilm non-producers.

3. **Statistical analysis**

Data was entered into Microsoft excel data sheet and was analysed using SPSS 22 version software (IBM SPSS Statistics, Somers NY, USA). Chi-square test was applied to test whether difference between values is significant. p value (Probability that the result is true) of <0.05 was considered as statistically significant after assuming all the rules of statistical tests.

4. **Result**

A total of 352 urinary isolates were analyzed for biofilm production and antimicrobial susceptibility testing. Of these, 258 were isolated from mid-stream urine specimens and 94 from urine of catheterized patients. Gram negative organisms were the predominant isolates from the urine specimens accounting for 83.24% (293), while Gram positive organisms were 16.76% (59). Enterobacteriaceae accounted for 88% (260) of Gram negative organisms with *E. coli* being isolated from more than half the urine specimens (55.12%) followed by *Klebsiella pneumoniae* (13%). Amongst non-Enterobacteriaceae Gram negative organisms (33), *Pseudomonas aeruginosa* were the most common, (29/33, i.e. 8.23%). *Enterococcus faecalis* (7.67%) were the most common Gram positive organism. (Table 3)

Biofilm production was observed in 47.44% of urinary isolates. Highest number of biofilm producers were *Pseudomonas aeruginosa* followed by *Escherichia Coli* & *Klebsiella pneumoniae* in case of Gram negative bacilli. In Gram positive cocci the rate of biofilm production was highest in *Enterococcus faecalis* (77.8%) followed by coagulase negative staphylococci (55.6%) (Table 1)

Rate of biofilm production was more in urinary isolates from catheterized patients (70.2%) as compared to non-catheterized patients (39.1%). (Table 2) In catheter associated urinary tract infection, rate of biofilm production increased as the days of catheterisation increased, being 30% in isolates from patients with less than 5 days of catheterisation and 80% in isolates from patients with more than 5 days of catheterisation.

Antimicrobial susceptibility pattern of Enterobacteriaceae isolated in the study shows that highest percentage sensitivity of the isolates (both biofilm producers as well as biofilm non producers) was observed to nitrofurantoin (81.92%), amikacin (79.23%) and imipenem (72.3%). (Table 3). The percentage susceptibility of *Pseudomonas aeruginosa* was found to be highest for piperacillin tazobactam (78.57%), amikacin (71.42%), imipenem (64.28%) and cefazidime (64.28%). (Table 4)

Amongst Gram positive cocci, the percentage susceptibility was found to be highest for nitrofurantoin (72.88%) followed by cotrimoxazole (42.37%) after vancomycin, linezolid and teicoplanin for which none of the isolate was found to be resistant. (Table 5)

Biofilm producing strains of all the isolates displayed higher percentage resistance to almost all tested antimicrobials than biofilm non producers.

5. **Discussion**

Urinary tract infections are a serious health threat with biofilm production being the prime cause for antibiotic resistance as well as recurrent infections.

In present study Gram negative bacilli accounted for 83.24% of cases and Gram positive cocci caused 16.76% of urinary tract infections. *Escherichia coli* (55.12%) was the commonest isolate found in urinary tract infection followed by *Klebsiella pneumoniae* (13.06%) and *Enterococcus spp.* (10.24%). These findings correlate well with the findings reported in studies conducted by Subramanian et al. (2012), Behzadi et al. (2010) and Noor et al. (2013).\(^9\)–\(^11\) The predominance of these bacteria in causing urinary tract infection is due the fact that they are the predominant gut flora and can easily contaminate the urethral meatus and can ascend to the bladder. In addition, the ability of the uropathogenic *Escherichia coli* (UPEC) to cause symptomatic UTIs is associated with the expression of a variety of virulence factors, which include adhesins (e.g., type 1 and P fimbriae) and toxins.\(^12\) The other Gram negative bacilli isolated were *Pseudomonas aeruginosa*
### Table 1: Microbiological spectrum of organisms isolated and biofilm production

| Organism                      | Total No. (n=352) | Percentage | Biofilm producers | Percentage |
|-------------------------------|-------------------|------------|-------------------|------------|
| *Escherichia coli*            | 194               | 55.12      | 87                | 44.32      |
| *Klebsiella pneumoniae*       | 46                | 13.06      | 19                | 41.3       |
| *Pseudomonas aeruginosa*      | 29                | 8.23       | 15                | 51.7       |
| *Enterococcus faecalis*       | 27                | 7.67       | 21                | 77.8       |
| *Coagulase negative staphylococci* | 18               | 5.11       | 10                | 55.6       |
| *Enterococcus faecium*        | 10                | 2.84       | 4                 | 40.0       |
| *Klebsiella oxytoca*          | 9                 | 2.55       | 4                 | 44.4       |
| *Proteus mirabilis*           | 7                 | 1.98       | 2                 | 28.6       |
| *Staphylococcus aureus*       | 4                 | 1.14       | 3                 | 75.0       |
| *Acinetobacter baumannii*     | 4                 | 1.14       | 0                 | 0.0        |
| *Citrobacter koseri*          | 4                 | 1.14       | 2                 | 50.0       |
| **Total**                     | **352**           | **100**    | **167**           | **47.44**  |

### Table 2: Biofilm production in urinary isolates from catheterized and non-catheterized patients of urinary tract infection

| Urinary isolates                      | Total No. of isolates | Biofilm production | Percentage |
|---------------------------------------|-----------------------|--------------------|------------|
| Urinary isolates from catheterized patients | 94                    | 66                 | 70.2       |
| Urinary isolates from non-catheterised patients | 258                  | 101                | 39.1       |

### Table 3: Antimicrobial susceptibility pattern of Enterobacteriaceae in percentage

| Antimicrobial                        | Biofilm producers (114) | Biofilm non producers (146) | Total (260) |
|--------------------------------------|--------------------------|-----------------------------|-------------|
| Ampicillin                           | 0                        | 2                           | 1.15        |
| Ampicillin sulbactam                  | 14.91                    | 23.28                       | 19.61       |
| Amoxycillin clavulanic acid          | 7                        | 21.91                       | 15.38       |
| Gentamicin                           | 34.21                    | 52                          | 44.23       |
| Amikacin                             | 72.8                     | 84.24                       | 79.23       |
| Netilmicin                           | 19.29                    | 52                          | 37.69       |
| Cefazolin                            | 8.77                     | 52                          | 33          |
| Cefotaxime                            | 15.78                    | 53.42                       | 36.92       |
| Ceftriazone                           | 11.4                     | 50                          | 33          |
| Ceftazidime                          | 10.52                    | 48.63                       | 31.92       |
| Cefepime                             | 12.28                    | 57.53                       | 37.69       |
| Ciprofloxacin                        | 10.52                    | 41.78                       | 28          |
| Ofloxacin                            | 17.54                    | 45.89                       | 33.46       |
| Levofloxacin                         | 18.42                    | 42.46                       | 31.92       |
| Norfloxacin                          | 17.54                    | 40.41                       | 30.28       |
| Nitrofurantoin                       | 77.19                    | 85.61                       | 81.92       |
| Cotrimoxazole                        | 24.56                    | 52.74                       | 40.38       |
| Tetracycline                         | 9.64                     | 34.93                       | 23.84       |
| Aztreonam                            | 10.52                    | 32.87                       | 23          |
| Imipenem                             | 67.54                    | 76                          | 72.3        |
| Piperacillin tazobactam              | 35                       | 63.69                       | 51.15       |
Table 4: Antimicrobial susceptibility pattern of *Pseudomonas aeruginosa* in percentage

| Antimicrobial       | Biofilm producers (15) | Biofilm non producers (14) |
|---------------------|------------------------|---------------------------|
| Gentamicin          | 20                     | 35.71                     |
| Amikacin            | 60                     | 71.42                     |
| Netilmicin          | 33.33                  | 50                        |
| Ceftazidime         | 20                     | 64.28                     |
| Cefepime            | 26.66                  | 57.14                     |
| Ciprofloxacin       | 20                     | 42.85                     |
| Ofloxacin           | 13.33                  | 28.57                     |
| Levofloxacin        | 20                     | 21.42                     |
| Norfloxacin         | 13.33                  | 21.42                     |
| Aztreonam           | 26.66                  | 57.14                     |
| Imipenem            | 46.67                  | 64.28                     |
| Piperacillin tazobactam | 40                 | 78.57                     |

Table 5: Antimicrobial susceptibility pattern of Gram positive cocci in percentage

| Antimicrobial       | Biofilm producers (38) | Biofilm non producers (21) | Total (59) |
|---------------------|------------------------|---------------------------|------------|
| Penicillin          | 15.78                  | 42.85                     | 23.72      |
| Ampicillin          | 15.78                  | 47.61                     | 27.11      |
| Vancomycin          | 100                    | 100                       | 100        |
| Linezolid           | 100                    | 100                       | 100        |
| Teicoplanin         | 100                    | 100                       | 100        |
| Ciprofloxacin       | 13.15                  | 52.38                     | 27.11      |
| Ofloxacin           | 26.31                  | 42.8                      | 32.2       |
| Levofloxacin        | 26.31                  | 57.14                     | 37.28      |
| Norfloxacin         | 23.68                  | 61.9                      | 37.28      |
| Nitrofurantoin      | 68.42                  | 80.9                      | 72.88      |
| Cotrimoxazole       | 31.57                  | 61.9                      | 42.37      |
| Tetracycline        | 18.42                  | 38                        | 25.42      |

Biofilm production was detected in 129 (44%) out of 293 Gram negative organisms and 38 (64.4%) out of 59 Gram positive organisms, by both tube as well as Congo red agar method. Thus total biofilm producing strains were 167 (47.44%). Discordant results were observed in 22 Gram negative and 8 Gram positive organisms i.e. they were positive by only one of the two methods.

Garcia et al (2004) have suggested that detection of slime production by the modified Christensen method and the Congo red agar method showed adequate positive predictive values (all above 80%) and they may therefore be useful in clinical decision making. They also concluded that Congo red agar method is less laborious, quicker and requires less equipment than tube method and it would be very useful in clinical microbiology laboratories. However, we feel that both the methods i.e. Christensen’s tube method and Congo red agar method are simple, cost effective and reproducible with an only disadvantage of subjective interpretation in case of tube test which can be eliminated by using spectrophotometric reading.

In this study 94 organisms were isolated from catheterized patients, of which 66 (70%) were found to be biofilm producing, while 101 (39%) of the 258 organisms isolated from the non-catheterised group were biofilm producers. The p value for biofilm formation in catheterised vs non-catheterised patients was found to be 0.001, which is highly statistically significant. This has been attributed to the fact that the catheter surface makes it an ideal site for bacterial attachment and biofilm formation.

In the present study the rate of biofilm production on the third and fifth days of catheterisation was 31.57% and 58.33% respectively. It increased further to more than 80% after the fifth day of catheterisation. This finding suggests that the chances of biofilm formation increases with the duration of catheterization. Longer the catheter remains in place; more are the chances of biofilm formation which correlates with studies by Tayal RA et al, Sabir N et al and Neeli VH et al. This may be because the longer time the catheter remains in the urinary system, it is highly likely that bacteria can colonize, accumulate in the residual urine in the bladder, adhere or aggregate, and form complex communities of bacterial species called biofilms.

Biofilm production on in-dwelling urinary catheters has been reported in a large number of studies conducted all over the world and is a major cause of nosocomial and recalcitrant UTI. The Catheter Associated Urinary Tract (8.23%), *Proteus mirabilis* (1.98%), *Citrobacter koseri* (1.14%) and *Acinetobacter baumannii* (1.14%).
Infection (CA-UTI) number upsurges every year since urinary catheters are the second most often used and internally placed human body foreign objects through which the causative organisms more easily attack the urinary tract and urinary bladder. Biofilms readily form on the inner or outer surfaces of these tubular latex or silicone devices. The ability of bacteria to form biofilms on medical devices, e.g. catheters, is believed to be a major role in the development of nosocomial infections, including catheter-associated urinary tract infections.

In the current study, we investigated antibiotic susceptibility patterns of biofilm producers and biofilm non producers against the drugs currently used in therapy of UTI. Almost all the biofilm producing isolates displayed relatively less percentage of susceptibility to tested antimicrobials than biofilm non producers. The resistance to antimicrobials in biofilm producing organisms may be due to the delayed penetration of the antibacterial agent, changes in microbial growth rate, metabolically inactive bacterial cells and other physiological alterations related to the development of the biofilm.

The fact that biofilm producers are more likely to be resistant to various antimicrobials, underscores the importance of early detection of biofilm production in a pathogen. If this information is received, as early as possible, it would aid in selecting the appropriate antimicrobial for treatment. In our study we attempted to provide this information at the earliest (within 24 hrs) by inoculating the urine sample on Congo red agar.

6. Conclusion

Antimicrobial resistance is an issue of global concern, and biofilm producing isolates show higher antimicrobial resistance as compared to biofilm non producers, as was evident in our study. Early information about the biofilm production by the infecting pathogen, by routine inclusion of detection methods in the laboratories, may be helpful in aiding the clinicians in deciding the appropriate empirical antimicrobial for the treatment of urinary tract infection. A simple method of inoculating the urine sample on Congo red agar along with the other routinely used media can serve as a simple, rapid and cost-effective way of providing this information at the earliest.

7. Source of Funding

None.

8. Conflict of Interest

The authors declare no conflict of interest.

References

1. Soto SM. Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches. Adv Biol. 2014;10:1–13.
2. Sumana E, Jose J, Varghese S, Kotian MS. Study of Biofilm Production in Escherichia coli Causing Urinary Tract Infection. Indian J Med Microbiol. 2005;25(3):305–6.
3. Tayal RA, Baveja SM, De AS. Analysis of biofilm formation and antibiotic susceptibility pattern of uropathogens in patients admitted in a tertiary care hospital in India. Int J Health Allied Sci. 2015;4(4):247–52.
4. Isenberg HD, Garcia LS. Urine cultures. In: Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology; 2010.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 27th informational supplement, M100-S27. Wayne PA: CLSI, 2017.
6. Freeman DJ, Falkiner FR, Keane CT. New method for detecting slime production by coagulase negative staphylococci. J Clin Pathol. 1989;42(8):872–74.
7. Abdagire NV, Chincholkar VV, Kulkarni DM, Nilekar SL, Birajdar SV. Biofilm production among uropathogens and their antibiogram. Int J Pharm Bio Sci. 2014;5:261–6.
8. Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun. 1982;37(1):318–26.
9. Subramanian P, Shanmugam N, Sivaraman U, Kumar S, Selvaraj S. Antibiotic resistance pattern of biofilm-forming uropathogens isolated from catheterised patients in Pondicherry, India. Australas Med J. 2012;5(7):344–8.
10. Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Cheshmehe AM, Omran SD. A survey on urine tract infections associated with the three most common uropathogenic bacteria. Maudica (Buchar). 2010;5(2):111–5.
11. Noor AF, Shams F, Munshi SK, Hassan M, Noor R. Prevalence and antibiogram profile of uropathogens isolated from hospital and community patients with urinary tract infections in Dha Creek. J Bangladesh Acad Sci. 2013;37:52–63.
12. Svanborg C, Godaly G. The bacterial virulence in urinary tract infections. Infect Dis Clin North Am. 1999;11:513–29.
13. Patraca G. Coagulase negative staphylococci: clinical, microbiological and molecular features to predict true bacteremia. J Medical Microbiol. 2004;53:67–72.
14. Sabir N, Ikram A, Zaman G, Satti L, Gardezi A, Ahmed A, et al. Bacterial biofilm-based catheter-associated urinary tract infections: Causative pathogens and antibiotic resistance. Am J Infect Control. 2017;45(10):1101–5.
15. Neeli VH, Parvathi T, Krishna PB. Study of Biofilm Production and Anti-microbial susceptibility pattern of bacterial and fungal isolates from urinary catheters. Int J Curr Microbiol App Sci. 2016;5(2):415–24.
16. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control. 2004;32(3):177–83.

Author biography

Ashwini Rajmane, Ex PG Student
Pankaj A Joshi, Associate Professor
Vishakha Shikhare, Associate Professor
Meena Ramteerthakar, Associate Professor
Vanita Kulkarni, Professor and HOD

Cite this article: Rajmane A, Joshi PA, Shikhare V, Ramteerthakar M, Kulkarni V. A study of biofilm production and antimicrobial susceptibility pattern among urinary isolates. Indian J Microbiol Res 2021;8(4):268–273.